Gideon Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gideon Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-32,513	Closed	-$859K	–	491
2019 Q1	$859K	Buy	32,513 +19,756	+155%	+$468K	0.31%	85
2018 Q4	$249K	Buy	+12,757	New	+$250K	0.1%	310

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gideon Capital Advisors's HZNP Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 32,513 shares — an estimated $859K sold.

Gideon Capital Advisors first reported a position in HZNP in Q4 2018 and held it in 2 quarters. The position peaked at $859K in Q1 2019. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

Gideon Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
Gideon Capital Advisors sold 32,513 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $859K.
Gideon Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 2 quarters.
Gideon Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $859K in Q1 2019.
272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.